MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
Triple Helix Framework
Industry
Architects: Small & Medium Size Business (SMBs), Product Development, De-Risking, Validation, Building Niche & Emerging Markets
*Architects: Infectious Disease_Hepatitis
Precision BioSciences, Inc. (NASDAQ: DTIL)*
Organization & Developments: Precision Biosciences
Parents
Precision BioSciences, Inc. (NASDAQ: DTIL)*
Children
* Project length: 3 years * Requested TIP funds: $2.7 M * Project total (est.): $5.4 M
*DNE is a proven technology with numerous successful applications in mammalian and plant cells.
*DNE is ushering in the era of "genomic molecular biology" and is already creating value across multiple facets of biotechnology.
*Precision BioSciences' Directed Nuclease Editor (DNE) is a robust platform for genome engineering.
*Project Goal: To create new tools for modifying the chemical structure of proteins that are produced by current biomanufacturing technologies to improve the therapeutic action of the manufactured protein.
*Reprogram a Mammalian Cell Line to Optimize Production of Biopharmaceuticals, Research Triangle Park, North Carolina
*The result is a DNE enzyme with the ability to precisely modify a specific, user-defined target within a genome.
*The targeted manipulation of genomic DNA has a broad range of applications including the correction of genetic disorders, the treatment of viral infections, the improvement of crops, and the engineering of cell lines for research or biomanufacturing.
*The technology is based on the production of custom-made DNA-cutting enzymes called "DNE meganucleases".
*Using state-of-the-art protein engineering techniques, Precision BioSciences alters the genetic sequence of a natural genome-editing meganuclease to create a custom meganuclease with unique DNA-recognition and cleavage properties.
2010: Precision BioSciences Awarded Over $3 Million from Four Government Grants (2010)
2010: Precision_Frost_release.pdf (applicationpdf ObjectFrost & Sullivan Names Precision BioSciences’ Directed Nuclease Editor ‘Technology Innovation of the Year (2010)
2019: Precision BioSciences Makes Impressive Progress On Mission To Change CAR-T Therapy Landscape_seekingalpha.com
2019: Precision Biosciences, Recent IPO: Unique ARCUS Gene Editing And Allogeneic CAR-T Platform_seekingalpha.com
2021: Precision BioSciences: New Gene Editing Company With Major Deals
2021: The Prognosis For Precision BioSciences
2022: Biotech Analysis Central Preview Series: Precision Biosciences seekingalpha.com
2025: FDA Greenlights First-Ever Hepatitis B Cure Attempt
2025: Precision & TG Therapeutics: Unlocking Value With ARCUS, BRIUMVI And Azer-Cel_seekingalpha.com
2025: Precision BioSciences Gene Therapy Shows Breakthrough Success in Infant OTC Deficiency Trial
2025: Precision BioSciences Strengthens Senior Leadership Team to Drive Multiple In Vivo Gene Editing Programs
Jumps
*Key People: Precision Biosciences
Finance & Acquisitions: Precision Biosciences